Frontier IP Group PLC (LON:FIPP) said The Vaccine Group, one of the companies in its investment portfolio, has appointed a chief executive officer.
The new man at the helm is Dr Jeremy Salt, who has extensive experience in senior roles in animal healthcare across organisations in the commercial and not-for-profit sectors. He joins The Vaccine Group from GALVmed, a not-for-profit organisation that develops and makes available livestock vaccines, medicines and diagnostics for small-scale livestock producers, where he was the chief scientific officer.
“The COVID-19 pandemic has raised the profile of vaccines as a key component of infectious disease control. The importance of multiple technological approaches to vaccine development has been shown to be critical. The Vaccine Group is well-positioned to contribute to this market with its novel vaccine platform technologies,” Salt said.
Neil Crabb, the chief executive of intellectual property firm Frontier IP, said Salt’s experience would be invaluable to The Vaccine Group.